Aelis Farma SAS: A Glimpse into the French Pharmaceutical Company

Aelis Farma SAS, a prominent player in the health care sector, is a French pharmaceutical company headquartered in Paris. The company is listed on the NYSE Euronext Paris, reflecting its significant presence in the European pharmaceutical market.

As of May 4, 2025, Aelis Farma SAS’s close price stood at 1.26 EUR. This figure is part of a broader financial narrative for the company, which has experienced considerable volatility over the past year. The company’s stock reached a 52-week high of 13.3 EUR on May 26, 2024, showcasing a period of strong investor confidence. However, the stock also hit a 52-week low of 1 EUR on April 6, 2025, indicating a challenging phase for the company.

The market capitalization of Aelis Farma SAS is currently 133,850,000 EUR. This valuation reflects the company’s standing in the market amidst fluctuating stock prices. The price-to-earnings (P/E) ratio stands at -2.32, suggesting that the company is not currently generating profits, which is a critical factor for investors to consider.

Aelis Farma SAS continues to operate within the dynamic and competitive health care sector, focusing on its core pharmaceutical activities. The company’s journey through the highs and lows of the stock market underscores the volatile nature of the pharmaceutical industry, where innovation and market conditions play pivotal roles in shaping financial outcomes.